Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Days Sales Outstanding : 37.72 (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Tonix Pharmaceuticals Holding Days Sales Outstanding?

Tonix Pharmaceuticals Holding's average Accounts Receivable for the three months ended in Dec. 2023 was $1.56 Mil. Tonix Pharmaceuticals Holding's Revenue for the three months ended in Dec. 2023 was $3.78 Mil. Hence, Tonix Pharmaceuticals Holding's Days Sales Outstanding for the three months ended in Dec. 2023 was 37.72.

The historical rank and industry rank for Tonix Pharmaceuticals Holding's Days Sales Outstanding or its related term are showing as below:

TNXP' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0 Med: 0 Max: 73.39
Current: 73.39

During the past 13 years, Tonix Pharmaceuticals Holding's highest Days Sales Outstanding was 73.39. The lowest was 0.00. And the median was 0.00.

TNXP's Days Sales Outstanding is ranked worse than
50.89% of 894 companies
in the Biotechnology industry
Industry Median: 72.38 vs TNXP: 73.39

Tonix Pharmaceuticals Holding's Days Sales Outstanding increased from Dec. 2022 (0.00) to Dec. 2023 (37.72).

Tonix Pharmaceuticals Holding Days Sales Outstanding Historical Data

The historical data trend for Tonix Pharmaceuticals Holding's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tonix Pharmaceuticals Holding Days Sales Outstanding Chart

Tonix Pharmaceuticals Holding Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

Tonix Pharmaceuticals Holding Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	35.73	37.72

Competitive Comparison of Tonix Pharmaceuticals Holding's Days Sales Outstanding

For the Biotechnology subindustry, Tonix Pharmaceuticals Holding's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Tonix Pharmaceuticals Holding's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tonix Pharmaceuticals Holding's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Tonix Pharmaceuticals Holding's Days Sales Outstanding falls into.

Tonix Pharmaceuticals Holding Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Tonix Pharmaceuticals Holding's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0)	/	1 )	/	7.768	*	365
=	0					/	7.768	*	365
=	0.00

Tonix Pharmaceuticals Holding's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1.562	+	0)	/	1 )	/	3.779	*	365 / 4
=	1.562					/	3.779	*	365 / 4
=	37.72

Tonix Pharmaceuticals Holding (NAS:TNXP) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Tonix Pharmaceuticals Holding Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Tonix Pharmaceuticals Holding's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Tonix Pharmaceuticals Holding (Tonix Pharmaceuticals Holding) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tonix Pharmaceuticals Holding Corp (NAS:TNXP) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

N/A

Address

26 Main Street, Suite 101, Chatham, NJ, USA, 07928

Website

https://www.tonixpharma.com

Tonix Pharmaceuticals Holding Corp is a clinical-stage biopharmaceutical company focused on developing therapeutics and vaccines to treat and prevent human disease and alleviate suffering. its portfolio consists of the central nervous system, rare disease, immunology, and infectious disease product candidates. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. CNS product candidate is TNX-102 SL, a proprietary sublingual tablet formulation of cyclobenzaprine (CBP) designed for bedtime administration.

Executives

Richard Newcomb Stillwell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Seth Lederman	director, 10 percent owner, officer: Chief Executive Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Carolyn E. Taylor	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 26 MAIN STREET, SUITE 101, CHATHAM NJ 07928
Daniel Wintner Goodman	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE, NEW YORK NY 10022
James Treco	director	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., NEW YORK NY 10022
Margaret Smith Bell	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Gregory M Sullivan	officer: Chief Medical Officer	C/O TONIX PHARMACEUTICALS HOLDINGS CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Richard H Bagger	director	C/O TONIX PHARMACEUTICALS HOLDING CORP., 509 MADISON AVE. - SUITE 1608, NEW YORK NY 10022
Adeoye Y Olukotun	director	3621 SOUTH STATE ST, 695 KMS PL, ANN ARBOR MI 48108
David L Grange	director
Ernest Mario	director	20 FAIRMOUNT AVENUE, P.O. BOX 445, CHATHAM NJ 07928
Jessica Edgar Morris	officer: Chief Administrative Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Bradley Saenger	officer: Chief Financial Officer	C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
John B Rhodes	director	74 FIFTH AVENUE, NEW YORK NY 10011
Samuel R Saks	director	3180 PORTER DRIVE, PALO ALTO CA 94304